Intra-Aortic Balloon Pump
IABP Performance Evolved
Indications for Use:The AC3™ IABP Series IABP (Intra Aortic Balloon Pump) system is clinically indicated for the following conditions; 1) Acute Coronary Syndrome, 2) Cardiac and Non-Cardiac Surgery, 3) Complications of Heart Failure Contraindications: Intra-Aortic Balloon Pumping (IABP) requires an adequate location in which to place the balloon and a functional aortic valve. Further, the clinician must have confidence that the patient will benefit from the procedure. The conditions described below are contraindications. Absolute
- Hemodynamically Significant or Severe Aortic Valve Insufficiency – If an aortic valve is incompetent, inflation of an IAB will result in increased regurgitation into the left ventricle. The flow of blood back into the left ventricle will reduce forward CO, further aggravating the patient’s abnormal hemodynamics.
- Aortic Aneurysm or Aortic Wall Disease (Including Dissection) – Movement of an IAB may jeopardize the integrity of the aortic wall in a patient with either of these conditions. Use of the IAB in patients with aortic dissection or suspected dissection should be avoided until the integrity of the aortic wall is established as rupture of the aortic wall may result from IAB use.
- Atherosclerosis or Severe Peripheral Vascular Disease (PVD) – In some patients with severe atherosclerosis, the femoral arteries may be sufficiently plaque-filled and tortuous to prevent placement of the balloon. The presence of significant PVD is a predictor of IAB related
- End-stage Disease or Sepsis – Use of IABP may not be justified in some patients with late-stage terminal illness. This is an aggressive and invasive procedure and should be used only if the patient will derive significant clinical benefit. Sepsis is contraindicated due to the risk of catheter or insertion site
- Severe Coagulopathy – Use of the IABP may not be justified in patients with severe clotting disorders as the IABP has been shown to increase the risk of bleeding complications.